A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers

Inclusion Criteria: * From 18 to 50 years old in phase 1, from 12 to 75 years old in phase 2 * Body Mass Index (BMI) between 18 and 28 kg/m2 * The subject has good health, is assessed through medical history, clinical examination, and laboratory tests (such as hematology, biochemistry, urine ...) within the normal range evaluated by the clinician. * Subjects aged potentially pregnant should use effective contraceptive methods 4 weeks prior to screening and during the study and last until 6 months after the last injection. * Able and willing to participate in all activities in the clinical trial, including 6-month follow-up after vaccination. * Sign the consent form. For a subject from 12 to 17 years old, it is necessary to have a legal guardian sign the consent form to participate in the study Exclusion Criteria: * Insufficient civil act capacity. * Subjects at high risk of SARS-CoV-2 infection. * Subject is/has ever had any acute or chronic medical condition, including but not limited to: * Have any inflammatory disease, respiratory tract infection, have any respiratory symptoms such as: cough, sore throat, difficulty breathing, wheezing due to respiratory symptoms within 07 days before screening. Fever (armpit temperature ≥ 37°C) for 3 days before vaccination. * History of any chronic respiratory illness such as bronchial asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease (COPD). * Malignant disease * Immune disorders, using immunosuppressive therapy. * Cardiovascular diseases (including high blood pressure requiring drug treatment), liver disease, chronic kidney disease, endocrine diseases (including diabetes), hemoglobin disease ... * Neurological, psychiatric, epilepsy, or Guillian-Barré disorders. * Pathology of hemostasis. * Having any surgery for 8 weeks before screening. * History of organ transplantation. * Examination and testing results at the time of screening: * Systolic pressure above 140 mmHg and/or diastolic pressure over 90mmHg; * Systolic blood pressure less than 90 mmHg and/or diastolic pressure below 50 mmHg * Real-Time nasopharyngeal fluid test - PCR (positive) and/or anti S - IgG (positive) with SARS-CoV-2. * Women of potential pregnancy, a positive urine beta-hCG test at the time of screening. * Positive with HIV, hepatitis B (HBsAg), hepatitis C (ANTI-HCV) tests * WBC less than 3.5 x 10\^9 cells / L * Lymphocytes of less than 1.0 x 10\^9 cells / L. * Neutrophils less than 2.0 x 10\^9 cells / L * Platelets below 140 x 10\^9 cells / l * Hb less than 120 g/L for men and less than 100 g/L for women * ALT or AST is over 2 times the normal limit * eGFR of 90 mL/min/ 1.73m2 or less. * Abnormal ECG of clinical significance. * The Subject who have taken any drugs or treatments simultaneously and before: * Any drug or treatment that affects the immune system such as injectable anti-allergenic drugs, Globulin, Interferon, immunomodulators, cytotoxic drugs, or any other drug toxic to the body, for 90 days before screening. * Systemic steroids (oral or injectable; including intra-articular injection) regardless of dose except for topical form, for 28 days prior to screening. * Any vaccine within 28 days prior to screening or planned for in-study vaccination or after 6 months after the first vaccination. * Receive or donate blood/serum during the 8 weeks prior to the screening, or plan to receive or donate blood/serum during the study period. * The Subject that participated in any clinical trial 28 days prior to the screening date or intends to participate in another clinical study at any point in the study. * Women who are pregnant and breastfeeding or planning to become pregnant for the next 6 months from the time of the study 2 vaccines. * The Subject has a history of allergy to any of the vaccine components understudying or has a history of at least one past history of allergic or hypersensitivity reactions. * The Subject addicted to alcohol (drinking from 5 cups of alcohol daily, glasses of alcohol/can of beer), tobacco/water pipe addicts (smoking from 5 or more cigarettes), drug addiction, opioid dependence * The Subject is a member of the research team, sponsor employee, producer (Nanogen), and a person related by family (wife, husband, child, father, mother) with those subjects.